PTGX (Protagonist Therapeutics) Moat Score: 4/10 (As of Jul. 08, 2026)


PTGX Protagonist Therapeutics Inc PTGX
51 GF Score
Price $140.91
GF Value $61.27
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Protagonist Therapeutics Moat Score?

Protagonist Therapeutics PTGX +7.11% 51 Moat Score is 4 as of Jul. 08, 2026. GuruFocus rates PTGX with a GF Score™ of 51/100 and a GF Value™ of $61.27 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,394 Biotechnology companies, Protagonist Therapeutics ranks better than 88.74% on this metric.

Protagonist Therapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Protagonist Therapeutics has Narrow Moat: Protagonist Therapeutics Inc has a discernible but modest moat due to its valuable intellectual property and R&D capabilities in the biotech sector. However, it lacks strong brand strength and customer loyalty, limiting its competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Protagonist Therapeutics might have Narrow Moat - Discernible but modest moat.

Protagonist Therapeutics  (NAS:PTGX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Protagonist Therapeutics Moat Score Related Terms

PTGX vs IMVT, SYRE, MIRM: Moat Score Comparison

For the Biotechnology subindustry, Protagonist Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protagonist Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Protagonist Therapeutics's Moat Score falls into.


PTGX
51GF Score
Protagonist Therapeutics Inc PTGX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Protagonist Therapeutics (PTGX) has a Moat Score of 4 as of Jul. 08, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Protagonist Therapeutics ranks #157 out of 1394 companies in the Biotechnology industry, placing it in the top 11.3%.
Is Protagonist Therapeutics' Moat Score too high?
Protagonist Therapeutics' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Protagonist Therapeutics' value of 4 is 100% above this industry median. Based on the distribution chart, Protagonist Therapeutics ranks #157 out of 1394 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Protagonist Therapeutics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Protagonist Therapeutics' Moat Score compare to IMVT and SYRE?
According to the Biotechnology industry distribution chart, Protagonist Therapeutics ranks #157 out of 1394 companies for Moat Score. This places Protagonist Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Protagonist Therapeutics' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protagonist Therapeutics's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protagonist Therapeutics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagonist Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protagonist Therapeutics (PTGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $61.27, compared to a current price of $140.91 — trading 130% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Protagonist Therapeutics' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Protagonist Therapeutics (PTGX), the current Moat Score is 4 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Protagonist Therapeutics (PTGX) Overvalued in 2026?

Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued. The current stock price of $140.91 is trading 130% above its estimated GF Value™ of $61.27. GuruFocus considers Protagonist Therapeutics to be Significantly Overvalued.

Key valuation signals for PTGX:

  • Moat Score: 4
  • GF Value™: $61.27 vs. price of $140.91 (130% above fair value)
  • GF Score™: 51/100 with 7 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1394)

No single metric tells the full story. See the PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protagonist Therapeutics Business Description

Address 7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
51GF Score

Get the complete analysis for PTGX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$140.91
Price
$61.27
GF Value